CA2274585A1 - Polypeptides de liaison a l'annexine v derives de l'hbsag et utilisation de ces dernieres - Google Patents
Polypeptides de liaison a l'annexine v derives de l'hbsag et utilisation de ces dernieres Download PDFInfo
- Publication number
- CA2274585A1 CA2274585A1 CA002274585A CA2274585A CA2274585A1 CA 2274585 A1 CA2274585 A1 CA 2274585A1 CA 002274585 A CA002274585 A CA 002274585A CA 2274585 A CA2274585 A CA 2274585A CA 2274585 A1 CA2274585 A1 CA 2274585A1
- Authority
- CA
- Canada
- Prior art keywords
- hbsag
- binding
- annexin
- polypeptide
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 268
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 222
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 120
- 230000027455 binding Effects 0.000 title claims description 135
- 102000000412 Annexin Human genes 0.000 title description 6
- 108050008874 Annexin Proteins 0.000 title description 6
- 108090000672 Annexin A5 Proteins 0.000 claims abstract description 92
- 102000004121 Annexin A5 Human genes 0.000 claims abstract description 92
- 241000700721 Hepatitis B virus Species 0.000 claims abstract description 73
- 208000015181 infectious disease Diseases 0.000 claims abstract description 42
- 241000724709 Hepatitis delta virus Species 0.000 claims abstract description 28
- 230000003993 interaction Effects 0.000 claims abstract description 25
- 239000000427 antigen Substances 0.000 claims abstract description 19
- 108091007433 antigens Proteins 0.000 claims abstract description 19
- 102000036639 antigens Human genes 0.000 claims abstract description 19
- 208000002672 hepatitis B Diseases 0.000 claims abstract description 17
- 150000001875 compounds Chemical class 0.000 claims abstract description 8
- 241000282414 Homo sapiens Species 0.000 claims description 50
- 239000000203 mixture Substances 0.000 claims description 33
- 229960005486 vaccine Drugs 0.000 claims description 26
- 208000037262 Hepatitis delta Diseases 0.000 claims description 20
- 208000029570 hepatitis D virus infection Diseases 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- 210000002966 serum Anatomy 0.000 claims description 16
- 238000004519 manufacturing process Methods 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 11
- 230000000903 blocking effect Effects 0.000 claims description 11
- 239000013543 active substance Substances 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 150000003904 phospholipids Chemical class 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 230000002163 immunogen Effects 0.000 claims description 8
- 238000000338 in vitro Methods 0.000 claims description 8
- 239000002054 inoculum Substances 0.000 claims description 8
- 239000012472 biological sample Substances 0.000 claims description 6
- 239000000969 carrier Substances 0.000 claims description 5
- 238000011081 inoculation Methods 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 238000005406 washing Methods 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 208000005331 Hepatitis D Diseases 0.000 claims description 2
- 230000001900 immune effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 32
- 241000282577 Pan troglodytes Species 0.000 description 18
- 210000003494 hepatocyte Anatomy 0.000 description 18
- 230000009257 reactivity Effects 0.000 description 17
- 108010090804 Streptavidin Proteins 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 15
- 230000028993 immune response Effects 0.000 description 15
- 238000013507 mapping Methods 0.000 description 15
- 230000035772 mutation Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 241000283973 Oryctolagus cuniculus Species 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090001008 Avidin Proteins 0.000 description 9
- 230000005875 antibody response Effects 0.000 description 9
- 230000003053 immunization Effects 0.000 description 9
- 238000002649 immunization Methods 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 102000013415 peroxidase activity proteins Human genes 0.000 description 9
- 108040007629 peroxidase activity proteins Proteins 0.000 description 9
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 8
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 8
- 101000780122 Homo sapiens Annexin A5 Proteins 0.000 description 8
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000011575 calcium Substances 0.000 description 7
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 7
- 238000013207 serial dilution Methods 0.000 description 7
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000700605 Viruses Species 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000003362 replicative effect Effects 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 108091036055 CccDNA Proteins 0.000 description 4
- 239000002506 anticoagulant protein Substances 0.000 description 4
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000763 evoking effect Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010052285 Membrane Proteins Proteins 0.000 description 3
- 102000018697 Membrane Proteins Human genes 0.000 description 3
- 101150010882 S gene Proteins 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 230000009260 cross reactivity Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 235000018977 lysine Nutrition 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 3
- 108091011000 phospholipid binding proteins Proteins 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000004007 reversed phase HPLC Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 125000006850 spacer group Chemical group 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000004145 Annexin A1 Human genes 0.000 description 2
- 108090000663 Annexin A1 Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 101000872838 Hepatitis B virus genotype C subtype adr (isolate China/NC-1/1988) Small envelope protein Proteins 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 102100034349 Integrase Human genes 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 description 2
- 101001006139 Podospora anserina Heterokaryon incompatibility protein s Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 206010042566 Superinfection Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 239000004411 aluminium Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000010647 peptide synthesis reaction Methods 0.000 description 2
- 102000036213 phospholipid binding proteins Human genes 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DRHZYJAUECRAJM-DWSYSWFDSA-N (2s,3s,4s,5r,6r)-6-[[(3s,4s,4ar,6ar,6bs,8r,8ar,12as,14ar,14br)-8a-[(2s,3r,4s,5r,6r)-3-[(2s,3r,4s,5r,6s)-5-[(2s,3r,4s,5r)-4-[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-5-[(3s,5s, Chemical compound O([C@H]1[C@H](O)[C@H](O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@H]5CC(C)(C)CC[C@@]5([C@@H](C[C@@]4(C)[C@]3(C)CC[C@H]2[C@@]1(C=O)C)O)C(=O)O[C@@H]1O[C@H](C)[C@@H]([C@@H]([C@H]1O[C@H]1[C@@H]([C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@](O)(CO)CO3)O)[C@H](O)CO2)O)[C@H](C)O1)O)O)OC(=O)C[C@@H](O)C[C@H](OC(=O)C[C@@H](O)C[C@@H]([C@@H](C)CC)O[C@H]1[C@@H]([C@@H](O)[C@H](CO)O1)O)[C@@H](C)CC)C(O)=O)[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O DRHZYJAUECRAJM-DWSYSWFDSA-N 0.000 description 1
- SFNPDDSJBGRXLW-UHFFFAOYSA-N (3-methylsulfanylbutan-2-ylideneamino) n-methylcarbamate Chemical compound CNC(=O)ON=C(C)C(C)SC SFNPDDSJBGRXLW-UHFFFAOYSA-N 0.000 description 1
- YHQZWWDVLJPRIF-JLHRHDQISA-N (4R)-4-[[(2S,3R)-2-[acetyl-[(3R,4R,5S,6R)-3-amino-4-[(1R)-1-carboxyethoxy]-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]amino]-3-hydroxybutanoyl]amino]-5-amino-5-oxopentanoic acid Chemical compound C(C)(=O)N([C@@H]([C@H](O)C)C(=O)N[C@H](CCC(=O)O)C(N)=O)C1[C@H](N)[C@@H](O[C@@H](C(=O)O)C)[C@H](O)[C@H](O1)CO YHQZWWDVLJPRIF-JLHRHDQISA-N 0.000 description 1
- NKUHWWPUOXOIIR-CRCLSJGQSA-N (4r)-5-amino-4-[[(2s)-2-azaniumylpropanoyl]amino]-5-oxopentanoate Chemical compound C[C@H](N)C(=O)N[C@@H](C(N)=O)CCC(O)=O NKUHWWPUOXOIIR-CRCLSJGQSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 101100113576 Arabidopsis thaliana CINV2 gene Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 1
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 1
- 108091005462 Cation channels Proteins 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 241001533413 Deltavirus Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 101710142246 External core antigen Proteins 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000700739 Hepadnaviridae Species 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 101000957351 Homo sapiens Myc-associated zinc finger protein Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 101710084021 Large envelope protein Proteins 0.000 description 1
- 102100037611 Lysophospholipase Human genes 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100038750 Myc-associated zinc finger protein Human genes 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 108010058864 Phospholipases A2 Proteins 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101800001295 Putative ATP-dependent helicase Proteins 0.000 description 1
- 101800001006 Putative helicase Proteins 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- 241000220259 Raphanus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241000193803 Therea Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 238000007818 agglutination assay Methods 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 229940001007 aluminium phosphate Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000027645 antigenic variation Effects 0.000 description 1
- 238000000211 autoradiogram Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 102000036203 calcium-dependent phospholipid binding proteins Human genes 0.000 description 1
- 108091011005 calcium-dependent phospholipid binding proteins Proteins 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940027941 immunoglobulin g Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 150000002669 lysines Chemical class 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 108010087904 neutravidin Proteins 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- -1 phosphatidylserine Chemical class 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 210000005152 placental membrane Anatomy 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- VJZLQIPZNBPASX-OJJGEMKLSA-L prednisolone sodium phosphate Chemical compound [Na+].[Na+].O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)COP([O-])([O-])=O)[C@@H]4[C@@H]3CCC2=C1 VJZLQIPZNBPASX-OJJGEMKLSA-L 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention a pour objet des polypeptides dérivés de l'antigène de surface de l'hépatite B. Ces polypeptides peuvent agir par compétition avec l'interaction de l'antigène de surface de l'hépatite B/annexine V ou peuvent se lier à un composé ou un anticorps agissant par compétition avec l'interaction de l'antigène de surface de l'hépatite B/annexine V. L'invention traite également de ces polypeptides, et des anticorps de ces derniers dans le diagnostic, le traitement et la vaccination contre une infection par le virus de l'hépatite B et/ou le virus de l'hépatite de delta.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96870164.9 | 1996-12-30 | ||
| EP96870164 | 1996-12-30 | ||
| EP97870103 | 1997-07-11 | ||
| EP97870103.5 | 1997-07-11 | ||
| PCT/EP1997/007268 WO1998029442A1 (fr) | 1996-12-30 | 1997-12-23 | Polypeptides de liaison a l'annexine v derives de l'hbsag et utilisation de ces dernieres |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2274585A1 true CA2274585A1 (fr) | 1998-07-09 |
Family
ID=26144424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002274585A Abandoned CA2274585A1 (fr) | 1996-12-30 | 1997-12-23 | Polypeptides de liaison a l'annexine v derives de l'hbsag et utilisation de ces dernieres |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0948533A1 (fr) |
| JP (1) | JP2001508054A (fr) |
| AU (1) | AU736032B2 (fr) |
| CA (1) | CA2274585A1 (fr) |
| WO (1) | WO1998029442A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1315963A (zh) * | 1998-09-01 | 2001-10-03 | 基因创新有限公司 | 结合膜联蛋白的苯并二氮杂䓬类和苯并硫杂吖庚因衍生物和hbsag肽,其组合物和用途 |
| US7635680B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| ES2286247T3 (es) | 2001-02-21 | 2007-12-01 | Alavita Pharmaceuticals, Inc. | Proteinas anexinicas modificacdas y tratamiento de la trombosis. |
| US7635676B2 (en) | 2001-02-21 | 2009-12-22 | Alavita Pharmaccuticals, Inc. | Modified annexin proteins and methods for their use in organ transplantation |
| US7645739B2 (en) | 2001-02-21 | 2010-01-12 | Alavita Pharmaceuticals, Inc. | Modified annexin compositions and methods of using same |
| JP5261822B2 (ja) * | 2006-10-30 | 2013-08-14 | 株式会社先端生命科学研究所 | Ｂ型肝炎ウイルスｓ抗原の分析方法 |
| WO2017026241A1 (fr) * | 2015-08-07 | 2017-02-16 | 国立大学法人愛媛大学 | Méthode de dosage par spectrométrie de masse du virus de l'hépatite b |
| WO2017059878A1 (fr) | 2015-10-07 | 2017-04-13 | Humabs Biomed Sa | Anticorps neutralisant puissamment le virus de l'hépatite b et utilisations de ces derniers |
| CN111879932B (zh) * | 2020-06-24 | 2022-09-27 | 南方医科大学南方医院 | 乙型肝炎病毒(hbv)特异性b细胞表位检测方法及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI83662C (fi) * | 1980-07-17 | 1991-08-12 | Scripps Clinic Res | Diagnostik antikropp och foerfarande foer dess framstaellning. |
| EP0082789B1 (fr) * | 1981-12-22 | 1987-04-08 | Baylor College of Medicine | Composition immunologique et méthode pour virus hépatite B |
| JPS60162000A (ja) * | 1984-02-02 | 1985-08-23 | Chemo Sero Therapeut Res Inst | 新規ペプチド |
| WO1985004103A1 (fr) * | 1984-03-09 | 1985-09-26 | Scripps Clinic And Research Foundation | Vaccin synthetique du virus de l'hepatite b comprenant des determinants aussi bien des cellules t que des cellules b |
| NZ235315A (en) * | 1989-09-19 | 1991-09-25 | Wellcome Found | Chimaeric hepadnavirus core antigen proteins and their construction |
| IL102964A0 (en) * | 1991-08-26 | 1993-01-31 | Cytel Corp | Hla-restricted hepatitis b virus ctl epitopes |
| ES2146231T3 (es) * | 1992-07-08 | 2000-08-01 | Innogenetics Nv | Polipeptidos derivados de la endonexina 2 y que presentan una actividad de receptor del virus de la hepatitis b, y su utilizacion en composiciones diagnosticas y farmaceuticas. |
| WO1994005698A1 (fr) * | 1992-09-01 | 1994-03-17 | United Nations Industrial Development Organization | Peptide presentant une reactivite croisee avec l'antiserum a l'antigene de surface de l'hepatite b |
| GB9325772D0 (en) * | 1993-12-16 | 1994-02-16 | Smithkline Beecham Biolog | Novel compounds |
| GB9608626D0 (en) * | 1996-04-25 | 1996-07-03 | Univ College Of London | Hepatitis b monoclonal antibodies |
-
1997
- 1997-12-23 AU AU58601/98A patent/AU736032B2/en not_active Ceased
- 1997-12-23 EP EP97954465A patent/EP0948533A1/fr not_active Withdrawn
- 1997-12-23 WO PCT/EP1997/007268 patent/WO1998029442A1/fr not_active Application Discontinuation
- 1997-12-23 JP JP52960298A patent/JP2001508054A/ja active Pending
- 1997-12-23 CA CA002274585A patent/CA2274585A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998029442A1 (fr) | 1998-07-09 |
| JP2001508054A (ja) | 2001-06-19 |
| WO1998029442A9 (fr) | 2000-02-17 |
| AU736032B2 (en) | 2001-07-26 |
| AU5860198A (en) | 1998-07-31 |
| EP0948533A1 (fr) | 1999-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2685270C (fr) | Vecteurs d'expression destines a stimuler une reponse immunitaire et procedes de leur utilisation | |
| US5932224A (en) | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus | |
| Baumert et al. | Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate | |
| JP4394019B2 (ja) | Ｃ型肝炎ウイルスに対して細胞障害性ｔリンパ球反応を誘発するペプチド | |
| Cooreman et al. | Characterization of the reactivity pattern of murine monoclonal antibodies against wild-type hepatitis B surface antigen to G145R and other naturally occurring “a” loop escape mutations | |
| JP3738395B2 (ja) | Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ | |
| US6689363B1 (en) | Inducing cellular immune responses to hepatitis B virus using peptide and nucleic acid compositions | |
| US7368118B2 (en) | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus | |
| JP3657603B2 (ja) | Ｂ型肝炎のウイルスに対する細胞障害性ｔリンパ球の応答を誘発するペプチド | |
| Bichko et al. | Epitopes recognized by antibodies to denatured core protein of hepatitis B virus | |
| AU736032B2 (en) | Annexin V-binding polypeptides derived from HBsAg and their uses | |
| US20110243986A1 (en) | Polynucleotides allowing the expression and secretion of recombinant pseudo-virus containing foreign epitopes, their production, and use | |
| Hertogs et al. | Spontaneous development of anti-hepatitis B virus envelope (anti-idiotypic) antibodies in animals immunized with human liver endonexin II or with the F (ab') 2 fragment of anti-human liver endonexin II immunoglobulin G: evidence for a receptor-ligand-like relationship between small hepatitis B surface antigen and endonexin II | |
| De Meyer et al. | Characterization of small hepatitis B surface antigen epitopes involved in binding to human annexin V | |
| Gerlich et al. | Functions of hepatits B virus proteins and molecular targets for protective immunity | |
| AU8142201A (en) | Annexin V-binding polypeptides derived from HBsAg and their uses | |
| PT97632A (pt) | Processo de obtencao de polipeptidos relacionados com a proteina do antigenio de superficie do virus da hepatite b e de vacinas que os contem | |
| Clayton | Investigations into the surface antigens of Hepatitis B Virus | |
| CA2156416C (fr) | Peptides pour l'induction de reactions cytotoxiques des lymphocytes t au virus de l'hepatite b | |
| Persing | Identification and characterization of the presurface proteins of hepatitis B virus | |
| CA2594184A1 (fr) | Peptides pour l'induction de reactions cytotoxiques des lymphocytes t au virus de l'hepatite b | |
| AU9240198A (en) | Peptides for inducing cytotoxic T lymphocyte responses to Hepatitis B virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |